April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr. Jeffrey Infante on the Positive Results of Using Avelumab in Patients With Ovarian Cancer
November 10th 2015Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.
Watch
Dr. Maurie Markman on the Further Study of PD-1 Inhibitors in Ovarian Cancer
November 5th 2015Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, talks about use of PD-1 inhibitors in ovarian cancer and the lack of evidence pointing toward their functionality.
Watch
Key to New Treatments: Discovering What Turns a Hedgehog Off
October 14th 2015Researchers note that chronic Hedgehog (Hh) pathway stimulation has been shown in prostate, lung, and ovarian cancers, and that zinc levels decrease early in prostate cancer continuing to castration-resistant disease. Researchers are exploring whether or not zinc may suppress the autocatalysis in the Hh precursor and inhibit production of biologically active Hh ligand.
Read More
Dr. Kauff Discusses Remaining Questions in the Treatment of Patients With Uterine Cancer
October 8th 2015Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses unanswered questions regarding the treatment of patients with uterine cancer.
Read More
New Immunotherapy With Chemotherapy Shows Results in Ovarian Cancer
September 9th 2015A novel immunotherapy, EGEN-001, combined with pegylated liposomal doxorubicin (PLD) has demonstrated clinical benefit in recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients.
Read More
Primary Chemotherapy Before Surgery in Ovarian Cancer May Be Preferable
September 8th 2015Results of the CHORUS trial confirm the noninferiority of primary chemotherapy followed by surgery versus primary surgery and then chemotherapy, and show that performing chemotherapy first is associated with less morbidity and mortality in patients with newly diagnosed, advanced ovarian cancer.
Read More
Dr. Coleman Discusses the Toxicities Associated With Rucaparib in Patients With Ovarian Cancer
August 18th 2015Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.
Watch
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Read More
New Genome Characterization Center to Focus on Proteomics Across Tumor Types
July 27th 2015The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).
Read More
Peptide Vaccine Gains FDA Orphan Status in Ovarian Cancer
July 18th 2015The immunotherapy DPX-Survivac has been granted orphan drug designation as treatment ovarian cancer, based on early-phase research showing a robust immune response with the therapy in combination with low-dose cyclophosphamide.
Read More
Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer
July 2nd 2015Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Watch
Ovarian Cancer Immune Response May Be Restored by Fighting XBP1
June 11th 2015A team at Weill Cornell Medical College in New York that is studying ovarian cancer has not only discovered another mechanism by which tumors evade attack by the immune system, but is also devising a first-in-class potential treatment.
Read More
Patients With Ovarian Cancer Likely to Respond to Rucaparib Using Tumor Genetic Analysis
June 10th 2015Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.
Watch